Legal Notices







 

 







MultiCell is a leading-edge biopharmaceutical company committed to the development and commercialization of breakthrough therapeutics based on a portfolio of new drug candidates and patented drug development technology platforms. 

MultiCell leverages patented methods of modulating the human immune system to treat serious autoimmune diseases, including multiple sclerosis and type-1 diabetes, as well as influenza and other health threats.  Currently, the market for therapies addressing such conditions is estimated at $8 billion worldwide.

The Company's novel technologies include expertise in Toll-like receptors and T-cell targeting to modulate both the innate and adaptive immune systems, enabling the creation of advanced drug candidates that stimulate or suppress the immune system via disease-specific targeting of the immune system. 


Thu, Aug 20
2009 8:00 AM

 

MultiCell Technologies is Granted U.S. Patent for Immortalized Human Liver Cell Lines

Thu, Mar 19
2009 9:40 AM

 

MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer

Wed, Dec 26
2007 5:14 PM

 

MultiCell Technologies To Increase Focus on Therapeutic Candidates

Wed, Oct 10
2007 10:23 AM

 

MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated

Thu, July 19
2007 8:00 AM

 

MultiCell Technologies and Fusion Capital Terminate Common Stock Purchase Agreement



[more news...]